Inflation Reduction Act a Blessing in Disguise for Drug Stocks?
Coming limits on drug pricing may not be bad news for drug makers after all.
At first glance, the measures to curb drug price increases in the Inflation Reduction Act seem like negatives for pharma and biotech stocks. If passed, as expected, Medicare would be allowed to negotiate the price it pays for a limited number of drugs. Beginning in 2026, up to 10 of Medicare’s highest-cost drugs would be included in negotiations, rising to the top 20 by 2029. In 2025, an annual $2,000 cap would be introduced on Medicare beneficiaries’ out-of-pocket prescription drug costs. But strategists at UBS Securities see some silver linings.
“We think the news is supportive,” says Mark Haefele, global wealth management chief investment officer at UBS. By reducing uncertainty and establishing a more predictable pricing outlook, the legislation could remove a long-standing overhang on the sector.
Other provisions in the bill will partially offset the negative financial impact. Expanded health-insurance subsidies that this legislation funds would enable more people to afford prescription drugs and potentially increase overall sales. And the proposal to cap out-of-pocket spending should make prescription drugs more affordable for Medicare’s high-use elderly population. Overall, according to UBS estimates, the impact equates to less than 3% of global biopharma industry earnings over a 10-year time frame.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Meanwhile, health care stocks are especially attractive now, according to UBS. Large-cap pharma companies typically offer steadily growing dividends. "We think investing in income stocks like these can help investors during an economic slowdown," says Haefele. UBS notes that during the early 2000s downturn, earnings per share for the MSCI World Index fell 50.7% peak-to-trough; dividends per share declined just 11.9%.
Because of the sector’s defensive characteristics and its ability to reduce volatility in your portfolio, UBS rates health care as “most preferred” in their global equity strategy. Other parts of the sector, such as medtech, also offer attractive long-term growth.
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Anne Kates Smith brings Wall Street to Main Street, with decades of experience covering investments and personal finance for real people trying to navigate fast-changing markets, preserve financial security or plan for the future. She oversees the magazine's investing coverage, authors Kiplinger’s biannual stock-market outlooks and writes the "Your Mind and Your Money" column, a take on behavioral finance and how investors can get out of their own way. Smith began her journalism career as a writer and columnist for USA Today. Prior to joining Kiplinger, she was a senior editor at U.S. News & World Report and a contributing columnist for TheStreet. Smith is a graduate of St. John's College in Annapolis, Md., the third-oldest college in America.
-
Stock Market Today: Stocks Pause as Investors Assess Fed Policy
The Federal Reserve met expectations with a quarter-point rate cut.
By David Dittman Published
-
Fed Cuts Rates Again: What the Experts Are Saying
Federal Reserve The central bank continued to ease, but a new administration in Washington clouds the outlook for future policy moves.
By Dan Burrows Published
-
Best Banks for High-Net-Worth Clients 2024
wealth management These banks welcome customers who keep high balances in deposit and investment accounts, showering them with fee breaks and access to financial-planning services.
By Lisa Gerstner Last updated
-
International Stocks: Time to Explore Investments Abroad
It's time for American investors to pack up their stay-at-home strategy and go shopping abroad for international stocks.
By Nellie S. Huang Published
-
Stock Market Today: Stocks Rise Ahead of Fed
Bank headlines dominated another choppy day of trading on Wall Street.
By Karee Venema Published
-
Stock Market Today: Stocks Struggle on Credit Suisse, First Republic Bank Concerns
Chaos in the financial sector stole the spotlight from this morning's inflation and retail sales updates.
By Karee Venema Published
-
Stock Market Holidays in 2024: NYSE, NASDAQ and Wall Street Holidays
Markets When are the stock market holidays? Here, we look at which days the NYSE, Nasdaq and bond markets are off in 2024.
By Kyle Woodley Last updated
-
Stock Market Trading Hours: What Time Is the Stock Market Open Today?
Markets When does the market open? While the stock market does have regular hours, trading doesn't necessarily stop when the major exchanges close.
By Michael DeSenne Last updated
-
Bogleheads Stay the Course
Bears and market volatility don’t scare these die-hard Vanguard investors.
By Kim Clark Published
-
The Current I-Bond Rate Until May Is Mildly Attractive. Here's Why.
Investing for Income The current I-bond rate is active until November 2024 and presents an attractive value, if not as attractive as in the recent past.
By David Muhlbaum Last updated